Phibro Animal Health (NASDAQ:PAHC) Lifted to Buy at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other analysts also recently weighed in on PAHC. Morgan Stanley cut their price target on Phibro Animal Health from $18.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Thursday. Roth Mkm reaffirmed a “buy” rating and issued a $21.00 target price on shares of Phibro Animal Health in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $18.25.

Phibro Animal Health Stock Performance

Shares of PAHC opened at $14.51 on Friday. The firm has a market cap of $587.66 million, a PE ratio of 20.44, a PEG ratio of 7.32 and a beta of 0.62. The stock’s fifty day moving average price is $14.62 and its two-hundred day moving average price is $14.72. The company has a debt-to-equity ratio of 1.71, a current ratio of 3.54 and a quick ratio of 1.77. Phibro Animal Health has a 1 year low of $11.75 and a 1 year high of $16.52.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Thursday, August 31st. The company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.02). Phibro Animal Health had a return on equity of 18.13% and a net margin of 2.92%. The firm had revenue of $255.00 million during the quarter, compared to analysts’ expectations of $256.68 million. During the same quarter in the previous year, the company posted $0.36 earnings per share. On average, equities research analysts forecast that Phibro Animal Health will post 1.23 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Comerica Bank acquired a new position in shares of Phibro Animal Health during the 2nd quarter worth about $3,877,000. Alliancebernstein L.P. raised its position in shares of Phibro Animal Health by 3.4% during the 2nd quarter. Alliancebernstein L.P. now owns 26,630 shares of the company’s stock valued at $365,000 after buying an additional 880 shares during the period. Wells Fargo & Company MN raised its position in shares of Phibro Animal Health by 1.0% during the 2nd quarter. Wells Fargo & Company MN now owns 206,345 shares of the company’s stock valued at $2,827,000 after buying an additional 2,041 shares during the period. Connors Investor Services Inc. raised its position in shares of Phibro Animal Health by 15.3% during the 2nd quarter. Connors Investor Services Inc. now owns 15,101 shares of the company’s stock valued at $207,000 after buying an additional 2,000 shares during the period. Finally, Royal Bank of Canada increased its holdings in Phibro Animal Health by 8.8% in the 2nd quarter. Royal Bank of Canada now owns 9,188 shares of the company’s stock valued at $127,000 after purchasing an additional 745 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.